NeurogesX Inc

NeurogesX — Technical Presentation (November 2011)

9 slides from NeurogesX's technical presentation, Nov 8, 2011

  1. Slide 1: NGX-1998 Phase 2 (C204 Study) Postherpetic Neuralgia Top-Line Results

    NGX-1998 Phase 2 (C204 Study) Postherpetic Neuralgia (PHN) Top-Line Results November 8, 2011 Exhibit 99.2

  2. Slide 2: Study Objectives

    Study Objectives 1. Assess preliminary safety and efficacy of 10% and 20% applied for 5 minutes 2. Assess preliminary dose response of 20% vs. 10% vs. Placebo 3. Determine if topical anesthetic pre-treatment required 4. Assess if inert placebo is an appropriate control to maintain the study blinding

  3. Slide 3: Phase 2 Study Design

    Placebo NGX-1998 (10%) NGX-1998 (20%) 30-min pre-treatment 15-min pre-treatment No pre-treatment Placebo NGX-1998 (10%) NGX-1998 (20%) Stage 1 Stage 2 No pre-treatment used in Stage 2 (based on Stage 1 results) Phase 2 Study Design 30-min pre-treatment 15-min pre-treatment No pre-treatment Pre-Rx fr

  4. Slide 4: Demographic Characteristics (Baseline)

    Placebo (N=33) NGX-1998 Total (N=164) 10% (N=66) 20% (N=65) Demographic Characteristics (Baseline) Average Age Gender (Male) 48% 48% 49% 49% Average Duration of PHN (Year) 3.1 3.3 4.1 3.6 Average NPRS Score (0-10) 5.9 6.2 6.1 6.1 Concomitant Neuropathic Pain Medications 49% 46% 49% 48%

  5. Slide 5: Pain Relief Maintained Through Weeks

    Pain Relief Maintained Through 12 Weeks Following a 5-minute application -35% -30% -25% -20% -15% -10% -5% 0% Placebo NGX-1998 (10%) NGX-1998 (20%) LS MEAN % CHANGE FROM BASELINE OF AVERAGE NPRS SCORES

  6. Slide 6: Dose Response Data

    Dose Response Data -30% -25% -20% -15% -10% -5% 0% Placebo (N=33) NGX-1998 (10%) (N=66) NGX-1998 (20%) (N=65) Wks 2-8 Wks 2-12

  7. Slide 7: Safety Results

    Placebo (N=33) NGX-1998 10% (N=66) 20% (N=65) Safety Results Adverse Events 67% 95% 100% Local Site Reactions 61% 89% 97% Serious Adverse Events 9% 5% 3% Discontinuation due to Adverse Events 0% 0% 0%

  8. Slide 8: C204 Top-Line Study: Our Conclusions

    C204 Top-Line Study: Our Conclusions All Study Objectives Were Met 1. Initial evidence of a dose response: Treatment Effect: 20% > 10% > Placebo 20% showed similar pain reduction profile to Qutenza 2. No topical anesthetic pre-treatment required 3. Excellent safety profile 4. Suggests true placebo i

  9. Slide 9: Safe Harbor

    Safe Harbor Forward looking statements may include, but are not limited to, statements regarding the utility of the data from the completed clinical trial of NGX- for designing future clinical trials, including potential for non-use of anesthetic pre-treatment and use of true placebo. Such statement

NeurogesX — Technical Presentation (November 2011) on 6ix